Financials

Company Profile

Scorpius Holdings, Inc. is not engaged in any business activities. The Company was previously a contract development and manufacturing organization.

Employees

Sector

Date	Price	Change	Volume
02/07/26	US$0.001100	-15.38%	1,924
30/06/26	US$0.001300	-76.79%	857

Delayed Quote OTC Markets

Market Closed - OTC Markets Other stock markets 15:18:59 02/07/2026 BST			5-day change	1st Jan Change
0.001100 ^USD	-15.38%		-80.36%	+450.00%

04-24	Scorpius Holdings, Inc. Announces Board and Committee Changes	CI
04-08	Scorpius Holdings, Inc. Announces Resignation of William Ostrander as Chief Financial Officer, Effective March 31, 2026	CI

04-24	Scorpius Holdings, Inc. Announces Board and Committee Changes	CI
04-08	Scorpius Holdings, Inc. Announces Resignation of William Ostrander as Chief Financial Officer, Effective March 31, 2026	CI
03-10	Scorpius Holdings, Inc. announced that it has received $0.031175 million in funding	CI
02-25	Scorpius Holdings, Inc. announced that it has received $0.219544 million in funding	CI
02-17	Scorpius Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
02-11	Scorpius Holdings, Inc. announced that it has received $0.030427 million in funding	CI
01-12	Scorpius Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
12-15	Scorpius Holdings, Inc. announced that it has received $0.044374 million in funding	CI
12-10	Velocity Bioworks, Inc. acquired All of Personal Property and Assets of Scorpius Holdings, Inc. for $16.3 million.	CI
12-02	Scorpius Holdings, Inc. Announces Issuance of Multiple Non-Convertible Promissory Notes with Customary Terms	CI
11-30	Scorpius Holdings, Inc. announced that it has received $0.1541 million in funding	CI
11-25	Scorpius Holdings, Inc. announced that it has received $0.724523 million in funding	CI
11-24	Scorpius Holdings, Inc. announced that it has received $0.03795 million in funding	CI

01/05/23	Brookline Capital Downgrades NightHawk Biosciences to Hold From Buy	MT
03/04/23	Maxim Downgrades NightHawk Biosciences to Hold From Buy	MT
18/03/22	B. Riley Lowers Heat Biologics' PT to $8 from $10, Adjusts Model for Higher Cost of Capital to Support Higher Operating Expenditures Ramp; Keeps Buy Rating	MT
15/03/22	Alliance Global Adjusts Heat Biologics' Price Target to $15.50 From $20, Reiterates Buy Rating	MT
24/01/22	B. Riley Lowers Heat Biologics' Price Target to $10 from $15 After Revising Cost Capital Assumptions, Keeps Buy Rating	MT

01-12	Scorpius : Quarterly Report for Quarter Ending June 30, 2025 (Form 10-Q)	PU
14/11/24	Scorpius : Reports Third Quarter 2024 Results, Highlighting Strategic Partnerships, Cost Savings, and Progress Toward Profitability Form 8 K	PU
22/10/24	Scorpius Holdings Announces Partnership with U.S. Biotech Company	AQ
02/10/24	Scorpius Holdings Selected to Join Medical CBRN Defense Consortium to Advance Medical Countermeasures Against Chemical, Biological, Radiological, and Nuclear Threats	AQ
30/09/24	Scorpius Holdings Announces Contract with Premier Clinical-Stage Biotech Company; Opens Door to Future GMP Manufacturing Opportunities	AQ

Manager	Title	Age	Since
Jeff Wolf CEO	Chief Executive Officer	63	31/03/2010
Joe Payne COO	Chief Operating Officer	-	-
David Waldman IRC	Investor Relations Contact	-	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
15/05/24	Jeff Wolf	Free	Chief Executive Officer	5,000,000	13.8766%
15/05/24	Seed-One Ventures LLC	Other	Company	0	0%
15/05/24	Orion Holdings LLC	Other	Company	0	0%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SCORPIUS HOLDINGS, INC.	-15.38%	-80.36%	-98.03%	-100.00%	67.26K
EINRIDE AB	+9.18%	+10.69%	-	-	1.18B
CHURCHILL CAPITAL CORP XI	+11.96%	+37.81%	-	-	1.06B
DRUGS MADE IN AMERICA ACQUISITION II CORP.	+0.20%	+0.40%	-	-	643M
CENTIEL AG	-0.32%	-19.32%	+288.68%	-68.79%	628M
CHURCHILL CAPITAL CORP XII	-0.37%	+2.97%	-	-	601M
BAIN CAPITAL GSS INVESTMENT CORP.	+0.29%	+0.10%	-	-	600M
CANTOR EQUITY PARTNERS IV, INC.	-0.10%	+0.44%	-	-	594M
AMERICAN EXCEPTIONALISM ACQUISITION CORP. A	+0.25%	+3.49%	-	-	586M
Average	+0.63%	+7.90%	+95.33%	-84.39%	655.35M
Weighted average by Cap.	+3.99%	+14.29%	+288.64%	-68.79%